Stem Cell Sanity?

On Monday, I noticed that a company related to stem cell research went public, just as news broke that one of the federally-approved embryonic stem cell lines is contaminated. Before checking out the stock price I thought,
Sarah Lacy

On Monday, I noticed that a company related to stem cell research went public, just as news broke that one of the federally-approved embryonic stem cell lines is contaminated. Before checking out the stock price I thought, "Well, ViaCell, welcome to life as a public company in the most news-driven, volatile niche of biotech.' Imagine my surprise when I saw the stock was up 5%.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.